Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes Haddad, R., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Kasper, S., Vokes, E. E., Worden, F., Saba, N. F., Tahara, M., Concha-Benavente, F., Monga, M., Lynch, M., Li, L., Shaw, J. W., Gillison, M. L., Harrington, K. J., Ferris, R. L. OXFORD UNIV PRESS. 2017
View details for Web of Science ID 000411324002231